Λευκωσία, 8 Μαΐου 2026 Τις προοπτικές που δημιουργούν οι εξελίξεις στη βιοτεχνολογία, στις προηγμένες θεραπείες, στην ιατρική ακριβείας και στην ψηφιακή υγεία ανέδειξε το διεθνές συνέδριο «Unlocking Europe’s Life Science Potential: A Policy Agenda for Competitiveness,...
Το συνέδριο διοργανώνει η ΚΕΦΕΑ σε συνεργασία με την EFPIA Λευκωσία, 30/4/2026 Η Κυπριακή Ένωση Φαρμακευτικών Εταιρειών Έρευνας και Ανάπτυξης (ΚΕΦΕΑ) σε συνεργασία με την Ευρωπαϊκή Ομοσπονδία Φαρμακευτικών Βιομηχανιών και Ενώσεων (EFPIA), διοργανώνει συνέδριο με τίτλο...
Μόλις 63 φάρμακα από τα 173 εγκεκριμένα από τις ευρωπαϊκές Αρχές διατίθενται στην Κύπρο την περίοδο 2020-23 Λευκωσία, 8 Μαΐου 2025 Η θέση της Κύπρου στην πρόσβαση ασθενών σε καινοτόμα φάρμακα παραμένει χαμηλή μεταξύ των ευρωπαϊκών χωρών, σύμφωνα με τα ευρήματα της...
29 January 2025 The Board of Directors of the Cyprus Association of Research & Development Pharmaceutical Companies (KEFEA) held a meeting on 29 January 2025 and decided as follows: With regard to section 19.9 of its Code of Conduct, KEFEA has made the decision to...
The Board of Directors of the Cyprus Association of Research & Development Pharmaceutical Companies (KEFEA) held a meeting on 31 January 2024 and decided as follows: With regard to section 19.9 of its Code of Conduct, KEFEA has made the decision to renew its white...
December 15, 2022 With regard to section 19.9 of its Code of Conduct, KEFEA has made the decision to establish a white list of 5* hotels in Cyprus, in which KEFEA members may hold and sponsor events, should they wish to do so. The white list was considered necessary...
With regard to section 19.9 of its Code of Conduct, KEFEA has made the decision to establish a white list of 5* hotels in Cyprus, in which KEFEA members may hold and sponsor events, should they wish to do so. The white list was considered necessary due to the paucity...
Paves the way to improve patients’ access to innovative medicines The Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA) welcomes the vote on the NHS bill by the House of Representatives Plenum. This is an important moment for the Republic...
NHS and falsified medicines top priorities of new Board Kyriakos Mikellis, Cyprus Business Manager at Pfizer, has been re-elected president of the Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA) for another two year term. In statements,...
KEFEA: Aim is to boost credibility at European level Transfers of value made by pharmaceutical companies involving the expenses incurred in relation to healthcare professionals and healthcare organisations are to be made public for the first time by the end of June as...
The Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA) is surprised by media reports claiming that 40% of pharmaceutical products at state pharmacies are inadequately labelled. In statements, KEFEA President Kyriacos Mikellis said that “as...
The implementation of a National Health System (NHS) that will guarantee high quality healthcare services as well as other important matters involving the pharmaceutical industry were discussed during the first meeting between Health Minister George Pamborides and the...
